NPS PHARMACEUTICALS INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2012-12-12: Form 8-K; Period of report 2012-12-12; Description 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 5.03.
- 2012-11-09: Form 8-K; Period of report 2012-11-09; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2012-08-01: Form 8-K; Period of report 2012-08-01; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2012-07-02: Form 8-K; Period of report 2012-06-29; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2012-12-12 | 8-K | 2012-12-12 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On December 12, 2012, the Company’s Board of Directors amended Sections 3.2.5 of its Amended and Restated Bylaws to adopt majority voting with respect to nominees for the Board of Directors at any meeting at which quorum is present and whereas of that date there are not more nominees than the number of directors to be elected. | a12-29040_18k.htm |
| 2012-11-09 | 8-K | 2012-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 On November 9, 2012, NPS Pharmaceuticals, Inc. issued a press release announcing its operating results for the third quarter of 2012. | a50470658.htm |
| 2012-08-01 | 8-K | 2012-08-01 | 2.02 Results of Operations and Financial Condition | 2.02 On August 1, 2012, NPS Pharmaceuticals, Inc. issued a press release announcing its operating results for the second quarter of 2012. | a50362430.htm |
| 2012-07-02 | 8-K | 2012-06-29 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Contract. 8.01 On July 2, 2012, the Company issued a press release announcing the Amendment to the License Agreement, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. | a50328473.htm |
| 2012-05-21 | 8-K | 2012-05-16 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On May 16, 2012, NPS Pharmaceuticals, Inc. (the “Company”) held its 2012 annual meeting of stockholders. | a12-12508_18k.htm |
| 2012-05-03 | 8-K | 2012-05-03 | 2.02 Results of Operations and Financial Condition | 2.02 On May 3, 2012, NPS Pharmaceuticals, Inc. issued a press release announcing its operating results for the first quarter of 2012. | a50263262.htm |
| 2012-02-29 | 8-K | 2012-02-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (d) On February 28, 2012, the Board of Directors (the “Board”) of NPS Pharmaceuticals, Inc. (the “Company”) increased the number of directors on the Board from eight to nine and elected Georges Gemayel as a director to fill the newly-created vacancy on the Board. | a12-6155_18k.htm |
| 2012-02-15 | 8-K | 2012-02-15 | 2.02 Results of Operations and Financial Condition | 2.02 On February 15, 2012, NPS Pharmaceuticals, Inc. issued a press release announcing its operating results for the fourth quarter and year ended December 31, 2011. | a50169192.htm |